Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort

Documenti analoghi

• Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
  di: Sanchez, Carlos Alberto, et al.
  Pubblicazione: (2010)
• Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART
  di: Uglietti, A, et al.
  Pubblicazione: (2010)
• Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption
  di: Labarga, Pablo, et al.
  Pubblicazione: (2010)
• Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
  di: Perez-Valero, I, et al.
  Pubblicazione: (2010)
• A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
  di: Izzo, I, et al.
  Pubblicazione: (2010)